Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Takeyasu, Y. [1 ]
Goto, Y. [1 ]
Morita, R. [1 ]
Sato, J. [1 ]
Murakami, S. [1 ]
Horinouchi, H. [1 ]
Fujiwara, Y. [1 ]
Kanda, S. [1 ]
Yamamoto, N. [1 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
519P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    [J]. LUNG CANCER, 2019, 137 : 113 - 122
  • [2] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [3] De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
    Takeda, Masayuki
    Okamoto, Isamu
    Fujita, Yoshihiko
    Arao, Tokuzo
    Ito, Hiroyuki
    Fukuoka, Masahiro
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (03) : 399 - 400
  • [4] STUDY OF THE SAFETY AND EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN 97 PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Ishibashi, M.
    Ogawa, K.
    Motizuki, S.
    Hanada, S.
    Uruga, H.
    Takaya, H.
    Miyamoto, A.
    Morokawa, N.
    Fujii, T.
    Kishi, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 433 - 433
  • [5] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Neutrophil to lymphocyte ratio (NLR) as a predictive marker of response to epidermal growth factor receptor (EGFR) tyrosine kinasc inhibitor (TKI) in EGFR mutation-positive non-small cell lung cancer (NSCLC).
    Vaidyanathan, Gayatri
    Dy, Grace K.
    Starostik, Petr
    Dibaj, Shiva
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [8] First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation - Positive non-small cell lung cancer patients
    Sequist, Lecia V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S143 - S145
  • [9] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [10] Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer
    Cascone, T
    Morelli, MP
    Ciardiello, F
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 46 - 48
12345